デフォルト表紙
市場調査レポート
商品コード
1559552

内分泌検査の世界市場

Endocrine Testing


出版日
ページ情報
英文 168 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.96円
内分泌検査の世界市場
出版日: 2024年09月24日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 168 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

内分泌検査の世界市場は2030年までに169億米ドルに達する見込み

2023年に120億米ドルと推定される内分泌検査の世界市場は、2023年から2030年にかけてCAGR 5.0%で成長し、2030年には169億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるタンデム質量分析技術は、CAGR 6.2%を記録し、分析期間終了時には53億米ドルに達すると予測されます。イムノアッセイ技術分野の成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は32億米ドルと推定、中国はCAGR 7.7%で成長予測

米国の内分泌検査市場は、2023年に32億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 7.7%で推移し、2030年には38億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と4.7%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の内分泌検査市場- 主要動向と促進要因のまとめ

内分泌検査はヘルスケアと疾病管理にどのような革命をもたらすか?

内分泌検査は、代謝、成長、生殖、健康全般の調節に重要な役割を果たす体内のホルモンシステムの機能に関する重要な洞察を提供することで、ヘルスケアと疾病管理に革命をもたらしています。この種の検査では、血液、尿、唾液のサンプルを分析してホルモンレベルを測定し、糖尿病、甲状腺疾患、副腎不全、生殖に関する健康問題など、さまざまな内分泌疾患の診断、監視、管理に役立てることができます。ホルモンバランスの乱れを正確に検出し、モニタリングすることは、効果的な治療を行うために不可欠です。検査技術の進歩により、内分泌検査はより正確で、利用しやすく、包括的なものとなり、ヘルスケアプロバイダーはより早期に状態を診断し、より効果的に治療を調整し、より正確に経過を観察することができるようになりました。内分泌系に対する理解が深まり、肥満、心血管疾患、骨粗しょう症などの慢性疾患との関連が明らかになるにつれ、内分泌検査は予防医療や個別化医療の要としてますます注目されています。

内分泌検査の機能を高めるイノベーションとは?

内分泌検査のイノベーションは、診断技術、自動化、個別化医療の進歩を通じて、その機能を強化しています。最も重要な進歩のひとつは、イムノアッセイや質量分析などの高感度で特異的なアッセイのイントロダクションです。これらの高度なアッセイによって、偽陽性や偽陰性の可能性が減少し、より信頼性の高い診断情報が得られます。内分泌検査ラボにおける自動化も重要な技術革新であり、最小限の人的介入でサンプルのハイスループット処理を可能にしています。これは、検査プロセスをスピードアップするだけでなく、ヒューマンエラーの可能性を減らし、一貫した正確な結果を保証します。さらに、内分泌検査と個別化医療アプローチとの統合は、ホルモン関連疾患の管理方法を変えつつあります。ホルモンレベルのデータを遺伝的、ライフスタイル的、環境的要因と組み合わせることで、ヘルスケアプロバイダーは各患者のユニークなニーズに対応したオーダーメイドの治療計画を作成することができ、転帰を改善し、合併症のリスクを減らすことができます。さらに、コルチゾールや甲状腺刺激ホルモン(TSH)のような特定のホルモンの家庭用検査キットの開発により、内分泌検査は一般の人々にとってより身近なものとなり、個人が便利かつ頻繁にホルモンレベルをモニターできるようになっています。このような技術革新により、内分泌検査はより正確で、効率的で、患者中心的なものとなり、内分泌疾患の診断と管理の改善を推進しています。

内分泌検査は疾患管理と患者の転帰にどのような影響を与えますか?

内分泌検査は、ホルモン関連疾患の早期診断、的を絞った治療、継続的なモニタリングを可能にすることで、疾患管理と患者の転帰に大きな影響を与えます。甲状腺機能亢進症、糖尿病、副腎不全などの内分泌疾患を早期に発見することで、タイムリーな介入が可能となり、疾患の進行を防ぎ、重篤な合併症のリスクを軽減することができます。例えば、内分泌検査を通じて甲状腺機能障害を早期に発見することで、未治療の甲状腺疾患から生じる可能性のある心臓病や精神衛生上の問題などの合併症を防ぐことができます。糖尿病のような慢性疾患の治療では、定期的な内分泌検査が血糖値のモニタリングに不可欠であり、必要に応じて治療計画を調整することで、最適な血糖コントロールを維持し、神経障害や心血管疾患などの合併症を予防することができます。また、ホルモン値を正確に測定・モニターできることで、ヘルスケアプロバイダーは治療を微調整することができ、薬剤の投与量を正確にし、個人のホルモンプロファイルに合わせた治療を行うことができます。このような個別化されたアプローチは、治療効果を向上させるだけでなく、患者のコンプライアンスと満足度を高める。内分泌疾患の管理を導く重要な情報を提供することで、内分泌検査は患者の転帰と生活の質の向上に重要な役割を果たしています。

内分泌検査市場の成長を促進する動向は?

内分泌疾患の有病率の上昇、診断技術の進歩、予防ヘルスケアへの関心の高まりなど、いくつかの動向が内分泌検査市場の成長を促進しています。糖尿病、甲状腺疾患、メタボリックシンドロームなどの疾患が世界的に増加しており、これらの疾患は継続的なモニタリングと管理が必要であるため、正確で包括的な内分泌検査の需要が高まっています。高齢者はホルモンバランスの乱れや関連疾患にかかりやすいため、高齢化もこの成長に寄与しています。次世代シークエンシングや高度免疫測定法などの診断技術の進歩は、内分泌検査をより正確で効率的なものにし、広く利用できるようにしており、市場の拡大をさらに促進しています。予防ヘルスケアを重視する傾向が強まっていることも重要な要因です。ホルモンバランスの乱れを早期に発見し管理することは、慢性疾患の発症を予防し、長期的な健康アウトカムを改善する上で極めて重要だからです。さらに、内分泌検査とデジタルヘルスプラットフォームや遠隔医療との統合は、これらの検査へのアクセスを拡大し、遠隔モニタリングやコンサルテーションを可能にしており、これは特にサービスが行き届いていない地域や地方の患者にとって有益です。また、内分泌検査と遺伝子やライフスタイルのデータを組み合わせて治療をカスタマイズする個別化医療の発展も、個別化医療のツールとしての内分泌検査の魅力を高めています。これらの動向は、内分泌検査が病気の予防、管理、個別化治療戦略の中心的な要素となることで、現代のヘルスケアにおける内分泌検査の重要性が増していることを浮き彫りにしています。

調査対象企業の例(合計 31注目)

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP11785

Global Endocrine Testing Market to Reach US$16.9 Billion by 2030

The global market for Endocrine Testing estimated at US$12.0 Billion in the year 2023, is expected to reach US$16.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Tandem Mass Spectrometry Technology, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 7.7% CAGR

The Endocrine Testing market in the U.S. is estimated at US$3.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Endocrine Testing Market - Key Trends and Drivers Summarized

How Is Endocrine Testing Revolutionizing Healthcare and Disease Management?

Endocrine testing is revolutionizing healthcare and disease management by providing critical insights into the functioning of the body’s hormonal system, which plays a vital role in regulating metabolism, growth, reproduction, and overall well-being. This type of testing involves analyzing blood, urine, or saliva samples to measure hormone levels, which can help diagnose, monitor, and manage various endocrine disorders, such as diabetes, thyroid diseases, adrenal insufficiencies, and reproductive health issues. The accurate detection and monitoring of hormone imbalances are essential for effective treatment, as even small deviations from normal levels can significantly impact a person’s health. With advancements in testing technologies, endocrine testing has become more precise, accessible, and comprehensive, allowing healthcare providers to diagnose conditions earlier, tailor treatments more effectively, and monitor progress with greater accuracy. As the understanding of the endocrine system deepens and its link to chronic diseases like obesity, cardiovascular diseases, and osteoporosis becomes clearer, endocrine testing is increasingly seen as a cornerstone of preventive and personalized medicine.

What Innovations Are Enhancing the Functionality of Endocrine Testing?

Innovations in endocrine testing are enhancing its functionality through advancements in diagnostic technologies, automation, and personalized medicine. One of the most significant developments is the introduction of highly sensitive and specific assays, such as immunoassays and mass spectrometry, which allow for the accurate quantification of even minute hormone levels in the body. These advanced assays reduce the likelihood of false positives and negatives, providing more reliable diagnostic information. Automation in endocrine testing labs is another key innovation, enabling high-throughput processing of samples with minimal human intervention. This not only speeds up the testing process but also reduces the potential for human error, ensuring consistent and accurate results. Additionally, the integration of endocrine testing with personalized medicine approaches is transforming the way hormone-related conditions are managed. By combining hormone level data with genetic, lifestyle, and environmental factors, healthcare providers can create tailored treatment plans that address the unique needs of each patient, improving outcomes and reducing the risk of complications. Furthermore, the development of at-home testing kits for certain hormones, such as cortisol or thyroid-stimulating hormone (TSH), is making endocrine testing more accessible to the general public, allowing individuals to monitor their hormone levels conveniently and frequently. These innovations are making endocrine testing more precise, efficient, and patient-centered, driving improvements in the diagnosis and management of endocrine disorders.

How Does Endocrine Testing Impact Disease Management and Patient Outcomes?

Endocrine testing has a profound impact on disease management and patient outcomes by enabling early diagnosis, targeted treatment, and ongoing monitoring of hormone-related conditions. Early detection of endocrine disorders, such as hyperthyroidism, diabetes, or adrenal insufficiency, allows for timely intervention, which can prevent the progression of the disease and reduce the risk of severe complications. For example, identifying thyroid dysfunction early through endocrine testing can prevent complications like heart disease or mental health issues that may arise from untreated thyroid disorders. In managing chronic conditions like diabetes, regular endocrine testing is essential for monitoring blood glucose levels and adjusting treatment plans as needed, helping to maintain optimal blood sugar control and prevent complications such as neuropathy or cardiovascular disease. The ability to measure and monitor hormone levels accurately also allows healthcare providers to fine-tune treatments, ensuring that medications are dosed correctly and that therapies are tailored to the individual’s hormonal profile. This personalized approach not only improves the effectiveness of treatment but also enhances patient compliance and satisfaction, as treatments are more likely to align with the patient’s specific needs and lifestyle. By providing critical information that guides the management of endocrine disorders, endocrine testing plays a vital role in improving patient outcomes and quality of life.

What Trends Are Driving Growth in the Endocrine Testing Market?

Several trends are driving growth in the endocrine testing market, including the rising prevalence of endocrine disorders, advancements in diagnostic technologies, and the increasing focus on preventive healthcare. The global rise in conditions such as diabetes, thyroid disorders, and metabolic syndromes is fueling demand for accurate and comprehensive endocrine testing, as these conditions require ongoing monitoring and management. The aging population is also contributing to this growth, as older adults are more susceptible to hormone imbalances and related diseases. Advancements in diagnostic technologies, such as next-generation sequencing and advanced immunoassays, are making endocrine testing more accurate, efficient, and widely available, further driving market expansion. The growing emphasis on preventive healthcare is another key factor, as early detection and management of hormone imbalances are critical in preventing the onset of chronic diseases and improving long-term health outcomes. Additionally, the integration of endocrine testing with digital health platforms and telemedicine is expanding access to these tests, allowing for remote monitoring and consultation, which is particularly beneficial for patients in underserved or rural areas. The development of personalized medicine approaches, which combine endocrine testing with genetic and lifestyle data to tailor treatments, is also enhancing the appeal of endocrine testing as a tool for individualized care. These trends highlight the increasing importance of endocrine testing in modern healthcare, as it becomes a central component of disease prevention, management, and personalized treatment strategies.

Select Competitors (Total 31 Featured) -

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Endocrine Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Prevalence of Endocrine Disorders Driving Demand for Testing
    • Technological Advancements in Diagnostic Tests Enhancing Accuracy and Speed
    • Integration of Telehealth and Remote Testing Options Expanding Accessibility
    • Impact of Lifestyle Diseases on the Growing Need for Endocrine Testing
    • Developments in Biomarker Discovery and Its Application in Endocrine Disorders
    • Future Outlook: AI Integration in Diagnostic Workflows for Endocrine Disorders
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Insulin Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Estradiol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Clinical Chemistry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Monoclonal & Polyclonal Antibody Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Sensors Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Endocrine Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: India 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION